Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis
1996

Outpatient Treatment of Advanced Seminoma with COC Regimen

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): S Sleijfer, PHB Willemsel, EGE de Vries, WTA van der Graaf, H Schraffordt Koops, NH Mulder

Primary Institution: University Hospital, Groningen, The Netherlands

Hypothesis

The study investigates the efficacy and toxicity of a combination chemotherapy regimen for advanced seminoma administered on an outpatient basis.

Conclusion

The COC regimen is feasible for outpatient treatment of advanced seminoma and shows a high response rate despite significant hematological toxicity.

Supporting Evidence

  • Six patients achieved a complete response (CR), while 19 had a partial response (PR).
  • The main toxicity observed was hematological, with 81% of patients experiencing thrombocytopenia.
  • After a median follow-up of 26 months, 25 out of 27 patients were alive without evidence of active disease.

Takeaway

Doctors used a mix of three medicines to treat patients with a type of cancer called seminoma, and it worked well for most of them, even though it made some of them feel sick.

Methodology

Patients received four cycles of chemotherapy consisting of cyclophosphamide, vincristine, and carboplatin, with evaluations of response and toxicity conducted throughout the treatment.

Limitations

The study had a small sample size and relatively short follow-up period.

Participant Demographics

Mean age of participants was 43 years, with a range of 28-63 years; six patients had prior radiotherapy.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI, 6-38% for CR; 95% CI, 51-88% for PR; 95% CI, 0-18% for NR

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication